Home Gynesonics


SONATA FDA IDE Pivotal Trial Long Term Results Published in the Journal of Gynecologic Surgery.

The outcomes reported in the paper build upon the previously published 12-month and 24-month outcomes, demonstrating the sustained durability of patient benefits through three years which include a significant reduction in fibroid related symptoms.

Gynesonics Announces Publication of CHOICES

Sonata demonstrates significant advantages in reducing procedure time, length of stay and procedure-related costs compared to myomectomy.

Gynesonics Reports Sonata System Assists Facilities Impacted by the COVID-19 Pandemic in Restarting Elective Gynecologic Procedures

Sonata integrates the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device to treat symptomatic fibroids in a transcervical, incision-free, uterus-preserving manner.

Next Generation Sonata® System 2.1 Receives FDA Market Clearance

The new advances in Sonata® System 2.1 include a new integrated treatment device design that enables all procedure steps to be performed on the sterile field and in the palm of the physician’s hand.